19:27 , Apr 15, 2019 |  BC Innovations  |  Distillery Therapeutics

CPS1 protein to treat drug-induced liver toxicity

DISEASE CATEGORY: Hepatic INDICATION: Drug-induced liver toxicity (DILI) Mouse studies suggest CPS1 could help treat DILI. In a mouse model of FASL-induced liver toxicity, CPS1 decreased serum levels of alanine transaminase (ALT), a marker of...
14:23 , Mar 19, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting FASL for ischemic stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Mouse studies suggest inhibiting FASL could help treat ischemic stroke. In a mouse model of middle cerebral artery occlusion (MCAO)-induced stroke, an anti-FASL mAb decreased ischemic brain injury and levels...
01:38 , Feb 15, 2019 |  BC Week In Review  |  Company News

3-V raises $18M, partners NASH program with Ascletis

3-V Biosciences Inc. (Menlo Park, Calif.) raised a $18 million series E round on Feb. 13 and granted lead investor Ascletis Pharma Inc. (HKEX:1672) exclusive rights in Greater China to TVB-2640, an inhibitor of fatty...
20:18 , Feb 13, 2019 |  BC Extra  |  Financial News

3-V raises $18M, partners NASH program with Ascletis

3-V Biosciences Inc. (Menlo Park, Calif.) raised a $18 million series E round and granted lead investor Ascletis Pharma Inc. (HKEX:1672) exclusive rights in Greater China to TVB-2640, an inhibitor of fatty acid synthase (FASN;...
13:31 , Feb 13, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); melanoma Mouse studies suggest inhibiting CD95 could help enhance the efficacy of adoptive T cell therapies for melanoma and ALL. In a mouse model of melanoma, adoptive transfer of T...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
18:17 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer, colorectal cancer Cell culture and mouse studies suggest inhibiting CPT1A alone or in combination with VEGF inhibition could help treat hepatocellular carcinoma and colorectal cancer. In a mouse colorectal cancer cell line...
15:18 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

China FDA approves IND for Canbridge's GBM candidate

Canbridge Life Sciences Ltd. (Beijing, China) said China FDA approved an IND to begin a Phase II/III trial of asunercept (APG101, CAN-008) to treat glioblastoma multiforme (GBM). A spokesperson told BioCentury that Canbridge plans to...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...